Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06079164 · ClinicalTrials.gov registry record · Phase 1
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
A Phase 1 study of Relapsed/Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company.
- Active
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 11
- Study locations
NCT06079164: Active Phase 1 study of Relapsed/Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company.
NCT06079164 is a Phase 1 study of Relapsed/Refractory Large B-cell Lymphoma that is active but no longer recruiting, run by Kite, A Gilead Company. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06079164, a Phase 1 study of Relapsed/Refractory Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Kite, A Gilead Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical study is learn about the effectiveness of the recommended dose of KITE-197 in participants with r/r LBCL. The primary objectives of this study are: Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the target dose level for Phase 1b. Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by the complete remission (CR) rate.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG KITE-197
Study Locations (11)
Other
- Cross Cancer Institute - Edmonton
- QEII Health Sciences Centre - Halifax
- Jewish General Hospital - Montreal
Florida
- Sylvester Comprehensive Cancer Center - Miami
Illinois
- University of Chicago Medical Center - Chicago
Tennessee
- Henry-Joyce Cancer Clinic - Nashville
Texas
- St. David's South Austin Medical Center - Austin
Washington
- Swedish Cancer Institute - Seattle
New South Wales
- Royal Prince Alfred Hospital - Camperdown
Queensland
- Royal Brisbane and Women's Hospital - South Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What the registry record for NCT06079164 still lists
NCT06079164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Relapsed/Refractory Large B-cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06079164 lists 11 locations in 9 states (Other, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT06079164 about?
NCT06079164 is a clinical study titled "Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma". This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical st...
What is the current status of trial NCT06079164?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2023-11-09. Estimated completion is 2026-07.
What conditions does trial NCT06079164 study?
This clinical trial studies the following conditions: Relapsed/Refractory Large B-cell Lymphoma.
What interventions are being tested in trial NCT06079164?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-197 (DRUG).
Who is sponsoring clinical trial NCT06079164?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06079164 being conducted?
This trial has 11 study locations across Florida, Illinois, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06079164's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI